Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis
- Creators
- Palandri, Francesca
- Bartoletti, Daniela
- Iurlo, Alessandra
- Bonifacio, Massimiliano
- Abruzzese, Elisabetta
- Caocci, Giovanni
- Elli, Elena M
- Auteri, Giuseppe
- Tiribelli, Mario
- Polverelli, Nicola
- Miglino, Maurizio
- Heidel, Florian H
- Tieghi, Alessia
- Benevolo, Giulia
- Beggiato, Eloise
- Fava, Carmen
- Cavazzini, Francesco
- Pugliese, Novella
- Binotto, Gianni
- Bosi, Costanza
- Martino, Bruno
- Crugnola, Monica
- Ottaviani, Emanuela
- Micucci, Giorgia
- Trawinska, Malgorzata M
- Cuneo, Antonio
- Bocchia, Monica
- Krampera, Mauro
- Pane, Fabrizio
- Lemoli, Roberto M
- Cilloni, Daniela
- Vianelli, Nicola
- Cavo, Michele
- Palumbo, Giuseppe A
- Breccia, Massimo
- Others:
- Palandri, Francesca
- Bartoletti, Daniela
- Iurlo, Alessandra
- Bonifacio, Massimiliano
- Abruzzese, Elisabetta
- Caocci, Giovanni
- Elli, Elena M
- Auteri, Giuseppe
- Tiribelli, Mario
- Polverelli, Nicola
- Miglino, Maurizio
- Heidel, Florian H
- Tieghi, Alessia
- Benevolo, Giulia
- Beggiato, Eloise
- Fava, Carmen
- Cavazzini, Francesco
- Pugliese, Novella
- Binotto, Gianni
- Bosi, Costanza
- Martino, Bruno
- Crugnola, Monica
- Ottaviani, Emanuela
- Micucci, Giorgia
- Trawinska, Malgorzata M
- Cuneo, Antonio
- Bocchia, Monica
- Krampera, Mauro
- Pane, Fabrizio
- Lemoli, Roberto M
- Cilloni, Daniela
- Vianelli, Nicola
- Cavo, Michele
- Palumbo, Giuseppe A
- Breccia, Massimo
Description
Background The presence of peripheral blasts (PB) is a negative prognostic factor in patients with primary and secondary myelofibrosis (MF) and PB >= 4% was associated with a particularly unfavorable prognosis. Ruxolitinib (RUX) is the JAK1/2 inhibitor most used for treatment of MF-related splenomegaly and symptoms. Its role has not been assessed in correlation with PB. Methods In 794 chronic-phase MF patients treated with RUX, we evaluated the impact of baseline percentage of PB on response (spleen and symptoms responses) and outcome (RUX discontinuation-free, leukemia-free, and overall survival). Three subgroups were compared: PB-0 (no PB, 61.3%), PB-4 (PB 1%-4%, 33.5%), and PB-9 (PB 5%-9%, 5.2%). Results At 3 and 6 months, spleen responses were less frequently achieved by PB-4 (P = .001) and PB-9 (P = .004) compared to PB-0 patients. RUX discontinuation-free, leukemia-free, and overall survival were also worse for PB-4 and PB-9 patients (P = .001, P = .002, and P < .001, respectively). Conclusions Personalized approaches beyond RUX monotherapy may be useful in PB-4 and particularly in PB-9 patients.
Abstract
The presence of peripheral blasts (PB) is a negative prognostic factor in patients with primary and secondary myelofibrosis (MF) and PB ≥4% was associated with a particularly unfavorable prognosis. Ruxolitinib (RUX) is the JAK1/2 inhibitor most used for treatment of MF-related splenomegaly and symptoms. Its role has not been assessed in correlation with PB.
Additional details
- URL
- http://hdl.handle.net/11567/1092127
- URN
- urn:oai:iris.unige.it:11567/1092127
- Origin repository
- UNIGE